DRB (Synonyms: NSC 401575,Benzimidazole) |
| Catalog No.GC17015 |
DRB는 카제인 키나제 II 및 CDK를 포함한 여러 카르복실 말단 도메인(CTD) 키나제를 억제하는 뉴클레오시드 유사체입니다. DRB는 건강한 세포에 유전 독성 스트레스를 유도하지 않고 인간 결장 선암종 세포의 p53 의존성 세포 사멸을 유발합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53-85-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a transcriptional elongation inhibitor.
Cyclin-dependent kinases (CDKs) belong to a family of protein kinases involved in regulating the cell cycle, transcription, mRNA processing, and the differentiation of nerve cells.[1] They are expressed in all known eukaryotes. With cyclin, CDK shows kinase activity. CDKs are serine-threonine kinases [1].
DRB inhibited the activity of several carboxyl-terminal domain (CTD) kinases including casein kinase II, Cdk7, Cdk8, and Cdk9 with the IC50 of 4-10 μM, ~20 μM, ~20 μM, and 3 μM) [2-5]. In HeLa cells, DRB (75 μM) inhibited 60-75% of nuclear heterogeneous RNA (hnRNA) synthesis. DRB (75 μM) reduced the appearance of labeled cytoplasmic poly(A)-containing messenger RNA (mRNA) by approximately 95%. DRB inhibited the initiation of hnRNA chains, but did not directly interfere with labeling of poly(A) [6]. DRB inhibited influenza virus multiplication in the chorioallantoic membrane in vitro [7]. DRB inhibited a HeLa protein kinase whihc phosphorylated an RNA polymerase II-derived peptide [8]. DRB can also inhibit HIV transcription (IC50 = ~4 μM) by targeting elongation enhanced by the HIV-encoded transactivator Tat.
References:
[1]. Zandomeni, R.O. Kinetics of inhibition by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole on calf thymus casein kinase II. Biochemistry Journal 262, 469-473 (1989).
[2]. Yankulov, K.,Yamashita, K.,Roy, R., et al. The transcriptional elongation inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. The Journal of Biological Chemisty 270(41), 23922-23925 (1995).
[3]. Rickert, P.,Corden, J.L., and Lees, E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 18, 1093-1102 (1999).
[4]. Schang, L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. Journal of Antimicrobial Chemotherapy 50, 779-792 (2002).
[5] Sehgal P B, Darnell J E, Tamm I. The inhibition of DRB (5, 6-dichloro-1-β-d-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells[J]. Cell, 1976, 9(3): 473-480.
[6] Tamm I, Tyrrell D A J. Influenza virus multiplication in the chorioallantoic membrane in vitro: kinetic aspects of inhibition by 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole[J]. The Journal of experimental medicine, 1954, 100(6): 541.
[7] Stevens A, Maupin M K. 5, 6-Dichloro-1-β-d-ribofuranosylbenzimidazole inhibits a HeLa protein kinase that phosphorylates an RNA polymerase II-derived peptide[J]. Biochemical and biophysical research communications, 1989, 159(2): 508-515.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *